- Poulia Ebrahim-pour
- - Endocrinology and Metabolism Research Center (EMRC), Tehran University of Medical Sciences, Tehran, Iran
- Peyman Shoushtari-zadeh
- - Endocrinology and Metabolism Research Center (EMRC), Tehran University of Medical Sciences, Tehran, Iran
- Vahid Hagh-panah
 - - Endocrinology and Metabolism Research Center (EMRC), Tehran University of Medical Sciences, Tehran, Iran
- Bita Rajabi-pour
- - Endocrinology and Metabolism Research Center (EMRC), Tehran University of Medical Sciences, Tehran, Iran
- Sasan Sharghi
- - Endocrinology and Metabolism Research Center (EMRC), Tehran University of Medical Sciences, Tehran, Iran
Received: 1/1/2005 Accepted: 1/1/2005 - Publisher : Avicenna Research Institute |
|
| Related Articles |
|
| Other Format |
|
|
|
Abstract
Introduction: Graves' disease (GD) is one of the autoimmune diseases in which the immune system over stimulates the thyroid gland, causing hyperthyroidism. Bone turnover is reported to increase in favor of resorption in overt hyperthyroidism and the rate of resorption is associated with the levels of thyroid hormones. As persistent increase in bone turnover is responsible for accelerated bone loss, patients with Graves' disease may have increased risk for osteoporosis. The aim of this study was to determine relationship between Graves' disease and bone markers. Materials and Methods The subjects of our study were 31 consecutive untreated GD patients and 37 normal volunteers which were matched on sex proportion and age range. GD was diagno-sed by suppressed levels of TSH and elevated levels of free T3 (fT3) and free T4 (fT4) and positive thyroid receptor antibody (TR). We investigated the relationship between serum osteo-calcin & cross-laps with Graves' disease and then kinds of treatment with PTU and Methimazole after 8 weeks follow up. Student T- test was used to compare the mean values and if necessary non- parametric statistics were used. 2 were used to compare the frequency of variables and if possible Exact Fisher Test was used. P- Values less than 0.05 were considered significant. Results: No significant differences in age and sex between patients and controls were found. Significant differences in serum bone markers and thyroid hormones were detected between patients and controls before therapy. After treatment we found a significant improvement and returning to normal range in all serum lab tests. There weren't any difference in the effect of treatment on thyroid hormones and bone markers between two groups. Conclusion: We found close relationship between Graves' disease and bone markers. So that treatment of Graves' disease can improve bone turnover. These findings indicated that early diagnosis and management of Graves' disease can be effective for osteoporosis prevention in these patients.
Keywords:
Graves disease, Bone markers, Osteoporosis, BMD, Thyroid, Hyperthyroidism To cite this article:References
- Leblond C.P., Fertman M.B., Puppel I.D., Cur-tis G.M. Radioiodine autography in studies of human goitrous thyroid glands. Arch Pathol Lab Med.1946;41:510.
- Sethi R., Blackburn P., Graves Disease. Medi-cal Conditions. Published by NHS, London,2005.
- اردلان محمدرضا. بيماري گريوز (Graves). مجله دانشگاه علوم پزشكي كردستان سال دوم، شماره هشتم، تابستان 77، صفحات: 38-29.
- Uzzan B., Campos J., Cucherat M., Nony P., Boissel J.P., Perret G.Y. Effects on bone mass of long term treatment with thyroid hormones: A meta-analysis. J Clin Endocrinol Metab. 1996;81: 4278-4289.
- Harvey R.D., McHardy K.C., Reid I.W., Paterson F., Bewsher P.D., Duncan A.,Robins P. Measurement of bone collagen degradation in hyperthyroidism and during thyroxine replace-ment therapy using pyridinium cross-links as specific urinary markers. J Clin Endocrinol Metab 1991;72:1189-1194.
- Krane S.M., Brownell G.L., Stanbury J.B., Corrigan H. The effect of thyroid disease on calcium metabolism in man. J Clin Invest.1956; 35:874.
- Follis R.H. Skeletal changes associated with hyperthyroidism. Bulletin of Johns Hopkins Hosp 1953;92:405.
- Soudry G., Donohoe K.J. Graves disease. Joint Program in Nuclear Medicine.1994.
- Moore E. Graves Disease. A Practical Guide, Published by McFarland, Colorado.2001.
- Vamos A., Balazs C., Korhaz K.G. Bone metabolism markers in patients with Basedow-Graves disease. Orv Hetil.1997;138:2403-5.
- Siddiqi A., Parsons M.P., Lewis J.L., Monson J.P., Williams G.R., Burrin J.M., TR expression and function in human bone marrow stromal and osteoblast-like cells. J Clin Endocrinol Metab. 2002;87:906-14.
- Longo B.C. Harrison's principles of internal medicine. 16th Edition McGraw Hill.2005.
- Mahaux J.E., Chamla-Soumenkoff J., Delcourt R., Levin S. Painful enlargement of left subtrape-zoid lymph nodes in Graves' disease. Br Med J. 1971;1:384.
- Weetman A.P. Graves' disease. N Engl J Med. 2000;26:1236-47.
- Siddiqi A., Burrin J.M., Noonan V., James V., Wood D. F., Price C. P., Monson J. P. A Longitudinal Study of Markers of Bone Turnover in Graves' disease and Their Value in Predicting Bone Mineral Density. J Clin Endocrinol Metab. 1997;82,753-759.
- Sugita E., Nagakura H., Fjsum, Taniyama M., Morita Y., Kawauchi A., Sjsum S., Katagirii T., Bany M. Evaluation of Bone Mass of Os Cal cis in Graves' Disease by Ultrasound Bone Densitometry: Third Department of Internal Med-icine, Department of Surgery, Showa University School of Medicine, 1-5-8,Hatanodai,Shinagawa- ku, Japan.